Protagonist Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $4,675 | $4,167 | $254,953 | $60,000 |
Gross Profit | 4,675 | 3,275 | 254,133 | 59,168 |
EBITDA | -40,806 | -38,793 | 207,129 | 23,881 |
EBIT | -41,453 | -39,685 | 206,309 | 23,049 |
Net Income | -33,210 | -30,616 | 207,340 | 27,335 |
Net Change In Cash | 4,675 | 4,167 | 254,953 | 60,000 |
Free Cash Flow | -28,638 | 268,594 | -27,671 | 16,941 |
Cash | 131,121 | 355,643 | 172,568 | 186,727 |
Basic Shares | 61,767 | 61,305 | 63,595 | 61,796 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $60,000 | $26,581 | $27,357 | $28,628 |
Gross Profit | 56,688 | 26,581 | 24,582 | 28,628 |
EBITDA | -90,340 | -128,004 | -123,070 | -63,662 |
EBIT | -93,652 | -131,373 | -125,845 | -64,451 |
Net Income | -78,955 | -123,413 | -122,627 | -66,150 |
Net Change In Cash | 60,000 | 26,581 | 27,357 | 28,628 |
Cost of Revenue | 2,169 | 6,198 | 84,177 | |
Free Cash Flow | -70,845 | -108,932 | -108,966 | -72,955 |
Cash | 186,727 | 125,744 | 123,665 | 117,358 |
Basic Shares | 56,763 | 49,042 | 46,322 | 34,396 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.54 |
2024-06-30 | -$0.50 |
2024-03-31 | $3.26 |
2023-12-31 | $0.44 |
